Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
CC transcript
Director departure
Appointed director

VOLITIONRX LTD (VNRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "VolitionRx Limited Announces Second Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Tuesday, August 15, at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 14, 2023 /PRNewswire/ -- VolitionRx Limited today announced financial results and a business update for the second quarter ended June 30, 2023. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. "I am delighted to report that we submitted a Breakthrough Device Designation Request to the FDA in June for our Nu.Q ® technology in relation to sepsis. This was a milestone moment in our company’s history and for the first time we are in active ..."
05/10/2023 8-K Quarterly results
Docs: "VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, May 11, at 8:30 a.m. U.S. Eastern Time"
11/14/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Conference call to discuss financial and operational results scheduled for Thursday, November 11, at 8:00 a.m. U.S. Eastern Time"
08/11/2021 8-K Quarterly results
Docs: "Conference call to discuss financial and operational results scheduled for Thursday, August 12, at 8:00 a.m. U.S. Eastern Time"
05/11/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "VolitionRx Limited Announces Third Quarter 2020 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, November 13 at 8:30 a.m. U.S. Eastern Time"
08/13/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/12/2019 8-K Quarterly results
Docs: "VolitionRx Limited Second Quarter 2019 Earnings and Business Update Conference Call  Date: Tuesday, August 13, 2019  Time: 8:30 a.m. U.S. Eastern time  U.S. & Canada Dial-in: 1-877 407 9716  U.K. Dial-in: 0 800 756 3429  Toll/International: 1-201 493 6779  Conference ID: 13693585 Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with David Vanston, Chief Financial Officer and Scott Powell, Executive Vice President, Investor Relations. The call will provide an update on recent developments and Volition’s activities, including details of new and ongoing clinical trials, important events which have taken place in the second quarter of 2019, and milestones for 2019 and beyond. About Volition Volition is..."
05/08/2019 8-K Quarterly results
Docs: "VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, May 9 at 8:30 a.m. U.S. Eastern Time AUSTIN, Texas, May 8, 2019 /PRNewswire/ -- VolitionRx Limited today announced financial results and a business update for the first quarter ended March 31, 2019. Volition management will host a conference call tomorrow, May 9, at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below. Cameron Reynolds, President and Chief Executive Officer of Volition, upon releasing these results, commented, “I could not be more proud of our dedicated team at Volition, and the ground-breaking work they are doing. During the first quarter, we, together with ou..."
11/07/2018 8-K Quarterly results
Docs: "VolitionRx Limited Announces Third Quarter 2018 Financial Results and Business Update ISNES, Belgium, November 7, 2018 /PRNewswire/ -- VolitionRx Limited today announced financial results and a business update for the quarter ended September 30, 2018. Volition management will host a conference call to discuss these results and provide a further business update tomorrow, November 8, at 8:30 AM U.S. Eastern Time. Cameron Reynolds, President and Chief Executive Officer of Volition, said, “We have had numerous highlights this quarter, with good progress being made on many fronts demonstrating the diverse nature of our platform technology. From a financial perspective I am delighted that we have strengthened the balance sheet in three ways: most importantly with completion of a private placeme..."
08/13/2018 8-K Quarterly results
Docs: "VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update ISNES, Belgium, August 13, 2018 /PRNewswire/ -- VolitionRx Limited today announced financial results and a business update for the quarter ended June 30, 2018. Volition management will host a conference call to discuss these results and provide a further business update tomorrow, August 14, at 8:30 AM U.S. Eastern Time. Cameron Reynolds, President and Chief Executive Officer of Volition, said, “We have had numerous highlights this quarter, with strong progress being made on many fronts. I am delighted with the broad strength of new talent in our team, especially the growth in our research and development team in Belgium who are hard at work on the considerable project of turning our assays into robust p..."
05/10/2018 8-K Quarterly results
Docs: "VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update ISNES, Belgium, May 10, 2018 /PRNewswire/ -- VolitionRx Limited today announced financial results and a business update for the first quarter ended March 31, 2018. Volition management will host a conference call tomorrow, May 11, at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below. Mr. Cameron Reynolds, President and Chief Executive Officer of Volition, said, “We have made great progress this quarter, moving our clinical assay development strongly forward and broadening our potential revenue base with our recently announced exclusive global license, manufacturing, sales and distribution agreement with Active Motif for a range of research use only kits.” Mr...."
11/09/2017 8-K Quarterly results
Docs: "VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update ISNES, Belgium, November 9, 2017 /PRNewswire/ -- VolitionRx Limited today announced financial results and a business update for the third quarter ended September 30, 2017. Volition management will host a conference call tomorrow, November 10, at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below. Mr. Cameron Reynolds, President and Chief Executive Officer of Volition, said, “We have made fantastic progress this quarter, moving our clinical product development strongly forward in Asia, Europe and the U.S, and broadening our potential revenue base with our recently announced research kit sales. We have further expanded our talented scientific team, with four new..."
08/09/2017 8-K Quarterly results
Docs: "VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update ISNES, Belgium, August 9, 2017 /PRNewswire/ -- VolitionRx Limited today announced financial results and a business update for the quarter ended June 30, 2017. Volition management will host a conference call to discuss these results and provide a further business update tomorrow, August 10, 2017 at 8:30 AM U.S. Eastern Time. Cameron Reynolds, President and Chief Executive Officer of Volition, said, “We have had numerous highlights this quarter, with strong progress being made on many fronts. I am delighted with the growing strength of new talent in our team, especially the growth in our Research and Development Team in Belgium. We are also fortunate to be working with institutions and individuals who hav..."
05/16/2017 8-K Form 8-K - Current report
11/15/2016 8-K Form 8-K - Current report
08/16/2016 8-K Quarterly results, Conference call transcript
Docs: "VolitionRx Announces Second Quarter 2016 Financial Results and Business Update",
"Transcript of Conference Call held on August 11, 2016"
05/19/2016 8-K Quarterly results, Conference call transcript
Docs: "VolitionRx Announces First Quarter 2016 Financial Results and Business Update Namur, Belgium, May 13, 2016 - VolitionRx Limited , a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the first quarter ended March 31, 2016. First Quarter 2016 and Recent Company Highlights:",
"Transcript of Conference Call held on May 13, 2016"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy